Plasma is the liquid portion of entire blood. It is composed generally of water and proteins, and it gives a medium for red blood cells, white blood cells and platelets to circulate through the body. Plasma is a critical part of the treatment which treats serious health problems. This is the reason, there are blood drives requesting people to donate blood plasma.
With the inclusion of water, salt, and enzymes, plasma also contains major components. These incorporate antibodies, clotting factors, proteins albumin and fibrinogen. When a person donate’s blood, healthcare providers can separate the vital parts from the plasma. The parts can then be concentrated into different products. These products are used as treatments that can help save the lives of people suffering from burns, trauma, shock, and other medical emergencies.
Plasma Therapy Company Market Segmentation:
By Product Type:
Pure PRP, Leucocyte-rich PRP, Pure Platelet-rich Fibrin (PRF), Leukocyte-rich Fibrin (L-PRF)
Orthopedics, Dermatology, Dental, Cardiac Muscle Injury, Nerve Injury, Others
The proteins and antibodies in plasma are used in therapies for chronic conditions. These incorporate autoimmune disorders and hemophilia. People with these conditions can live a long and productive lives because of the treatments. In fact, some health organizations refer plasma as "the gift of life."
The United States Food and Drug Administration approved Convalescent Plasma Therapy for COVID-19 patients as an experimental treatment in clinical trials. The report states as 11 critically ill COVID-19 patients in New York City and Houston have received this treatment using convalescent care. However, the results have not been reported till date. This therapy has also been conducted in several other countries.
Recently, Kerala has received Indian Council of Medical Research’s (ICMR) approval for the clinical feasibility of plasma transfusion, which may be administered to severe COVID-19 patients.
In China, about 10 COVID-19 patients took up convalescent therapy. In this treatment, the patients showed improved oxygen levels and a drop in the amount of virus in a person’s body as a reaction.
According to the study, the people who fought the COVID-19 virus, produce antibodies that are capable of attacking the virus. A patient who had recovered develops antibodies that would stay in their blood waiting to fight the same virus again.These antibodies and proteins that are secreted by immune cells known as B lymphocytes ( found in plasma) are taken by the researchers.By injecting those antibodies to another person with the disease, it would then recognise the virus and begin to attack the virus.
Brandessence Market Research has announced the Top 5 Plasma Therapy Company Market List In 2020
Over a century ago in Melbourne, Victoria, Australia, we made a promise to save lives and protect the health of people who were stricken with a range of serious and chronic medical conditions. Today, as a leading global biotech company, that same promise has never been stronger. We develop and deliver innovative biotherapies and influenza vaccines that save lives, and help people with life-threatening medical conditions live full lives. We are driven by our deep passion to serve hundreds of thousands of patients and other stakeholders around the world.
We focus on rare and serious diseases and influenza vaccines. Today, we compete on the global stage as one of the largest and fastest-growing protein-based biotechnology businesses and a leading provider of in-licensed vaccines.
CSL Behring and Takeda Pharmaceutical Are Leading a Coalition to Develop a COVID-19 Hyperimmune Therapy
Our five values –Ownership, Integrity, Leadership, Sustainability and Entreprenuership- guide our patient-oriented corporate culture. We aspire to embody these values in everything we do.
We are the largest privately owned and independent plasma fractionator in the world. Our medicines are high-quality human proteins sourced from human plasma and human cell lines. We develop and manufacture medicines for patients in three therapeutic areas: haematology, immunotherapy and critical care.
Kedrion SpA (“Kedrion”) is an international company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products for use in treating and preventing serious diseases, disorders and conditions such as hemophilia, Primary Immune Deficiency and Rh sensitization which can lead to hemolytic disease of the fetus and newborn.
Kedrion Biopharma Inc. (“Kedrion Biopharma”), the US subsidiary of Kedrion, is headquartered in Fort Lee, New Jersey.
Kedrion Biopharma launched US operations in 2011, but the company’s international roots stretch back several decades in the production of blood and plasma-derived products. It places a high value not only on the welfare of those who benefit from its products but also on the people and communities it serves.
Kedrion Developing Plasma Therapy for COVID-19
Grifols is a global company that since 1909 has enhanced the health and well-being of people around the world. Our four divisions - Bioscience, Diagnostic, Hospital and Bio Supplies - develop, produce and market innovative solutions and services in more than 100 countries.
Grifols, which has more than 2,000 employees in North Carolina, has begun identifying, screening and selecting volunteer donors who have recovered from COVID-19
At Biotest we work to provide effective help to patients with serious blood or immune diseases and to enable them to lead the most independent and normal lives possible. We manufacture and develop biological drugs that combine optimal efficacy with high tolerability and convenience of treatment. We apply the highest quality and safety standards in all phases of manufacturing and marketing. Within our clearly defined areas of activity, we continue to expand our expertise and position in special products.
Employees at Biotest are able to fully apply their abilities and expertise in their work, and to pursue both professional and personal growth. For us, acceptance, respect and equal treatment of all employees regardless of gender, age, nationality, skin colour, ideology or sexual orientation are a matter of course.
As a publicly listed company, we have the obligation to reach our shareholders’ interests, as well as those of our patients, users and employees. Our goal is to develop the company in such a way that it offers investors long-term a stable and profitable return.
Biotest AG: Biotest produces life-saving medicine derived from plasma from healed COVID-19 patients and participates in a cross-industry initiative
Interested in this report?
18 Feb 2021